Efficacy of early goal-directed therapy for hemodynamics stability in off-pump coronary artery bypass surgery Authors: Bui Quoc Khanh, Nguyen Chi Dung, Phung Van Viet, Bui Cong Doan, Bui Duc Thanh, Bui Thi Hoa, Pham Truong Son, Dinh Cong Pho Published: 2025 ABSTRACT Off-pump coronary artery bypass surgery causes hemodynamic changes due to position and surgical manipulation, which directly affect cardiovascular function and increase the rate of postoperative complications. The study’s goal was to evaluate the efficacy of early goal-directed therapy for hemodynamic stability in off-pump coronary artery bypass surgery. A case–control study was conducted between May 2022 and December 2024 in the Department of Anesthesiology and Critical Care at Military Hospital 175. Patients were monitored intraoperatively with ten time points using either the FloTrac/EV1000 system or conventional methods. Hemodynamic stability was measured by hemodynamic parameters (directly) and post-operative lactate levels (indirectly). The study included 70 patients (EGDT group: 36, Control group: 34). Baseline characteristics were similar between groups. Open surgery was performed in 90% of cases. Patients undergoing analysis recorded intraoperative hemodynamics with insignificant fluctuations of less than 5% in both groups. Both groups experienced a MAP nadir at T4 - post-anchoring suture (Control: 59.56 vs. EGDT: 62.42 mmHg). The EGDT group maintained significantly higher MAP After these points, the EGDT group showed faster MAP recovery. The EGDT implementation was associated with a 70% reduction in postoperative hyperlactatemia risk (OR 0.29; 95% CI 0.08–0.97; p = 0.023). Application of early goal-directed therapy in off-pump coronary artery bypass surgery showed hemodynamic stability, better control, and a statistical significance reduction in the risk of postoperative hyperlactatemia by 70%.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-28346-2. Introduction On-pump coronary artery bypass grafting (ONCAB) uses cardiopulmonary bypass (CPB) to maintain circulation. At the same time, the heart is stopped, but exposure of blood to the extracorporeal circuit can trigger systemic inflammatory response syndrome (SIRS), leading to myocardial dysfunction, acute kidney injury, neurological impairment, coagulopathy, respiratory complications, and multi-organ dysfunction1. To reduce such risks, off-pump coronary artery bypass grafting (OPCAB) is performed on a beating heart without CPB, thereby limiting inflammation and decreasing complications such as stroke, acute renal failure, and prolonged ventilation, while shortening recovery time. A randomized controlled trial and multiple meta-analyses have demonstrated that off-pump coronary artery bypass grafting, when compared to on-pump coronary artery bypass grafting, significantly reduces perioperative complications, including the rates of blood transfusion, reoperation due to bleeding, acute kidney injury, and respiratory complications2. However, OPCAB may result in less complete revascularization and higher rates of repeat intervention in some cases. Surgical choice should be individualized based on the patient’s condition and surgical expertise. However, some patients with left ventricular dysfunction may benefit from off-pump coronary artery bypass by avoiding the use of cardiopulmonary bypass. During OPCAB, manipulation of the beating heart results in hemodynamic fluctuations, including a decrease in systolic arterial pressure (SAP) and cardiac index (CI), and an increase in mean pulmonary artery pressure (PAP)3. These alterations reduce oxygen supply to the vulnerable myocardium, thereby increasing the need for inotropic agents and vasopressors, prolonging mechanical ventilation duration, and extending the length of stay in the intensive care unit4. Early Goal-Directed Therapy (EGDT) is a hemodynamic optimization strategy that aims to maintain preload, contractility, and afterload within optimal ranges through targeted fluid administration and the use of inotropic and vasoactive drugs4,5. EGDT has been shown to improve surgical outcomes by reducing the length of stay in the intensive care unit (ICU) and total hospital stay in high-risk patients undergoing cardiac surgery6,7. Several monitoring tools can be used to guide EGDT, including PiCCO plus, esophageal Doppler, Swan-Ganz pulmonary artery catheter, and the minimally invasive FloTrac/EV1000 system. The FloTrac/EV1000 system connects to a radial artery catheter and a central venous catheter, providing continuous, real-time hemodynamic parameters such as stroke volume variation (SVV), stroke volume index (SVI), cardiac index (CI), and systemic vascular resistance index (SVRI) without the need for calibration. Studies comparing EGDT using FloTrac/EV1000 with conventional hemodynamic management in cardiac surgery patients, including those undergoing off-pump coronary artery bypass and on-pump coronary artery bypass, have demonstrated that EGDT significantly reduces ICU and hospital length of stay8,9. While EGDT has robust evidence supporting its benefits in ONCAB, fewer studies have assessed its benefits in OPCAB4. To provide the evidence and deeply demonstrated EGDT in OPCAB, we conducted this research to evaluate the efficacy of early goal-directed therapy for hemodynamic stability in off-pump coronary artery bypass surgery. Materials and methods A cross-sectional, case-control study was conducted between May 2022 and December 2024 in the Department of Anesthesiology and Resuscitation at Military Hospital 175. Inclusion criteria were patients scheduled for elective off-pump coronary artery bypass (OPCAB) surgery without the use of cardiopulmonary bypass or combined vascular procedures; New York Heart Association (NYHA) functional classes I to III; Without preoperative liver dysfunction and chronic kidney disease requiring regular dialysis; Patients with normal preoperative blood lactate levels within the standard reference range (approximately 0–2 mmol/L). Exclusion criteria were conversion to cardiopulmonary bypass during surgery, Intraoperative use of intra-aortic balloon pump (IABP), and Occurrence of cardiac arrhythmias during surgery. Within the off-pump coronary artery bypass grafting (OPCAB) procedure, patients were selected based on specific preoperative criteria for advanced minimally invasive hemodynamic monitoring using Flotrac (patients with an ejection fraction (EF) below 50% and/or severe left main coronary artery disease). Sample size calculation The sample size was determined based on the comparison of mean values between two independent groups using the formula:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$N=\:\frac{({Z}_{1-\beta\:}+{Z}_{1-\alpha\:/2})^2({\sigma\:}_{1\:\:}^{2}+{\sigma\:}_{2\:\:}^{2})}{(\:{\mu\:}_{1}-\:{\mu\:}_{2})^2}$$\end{document} With α set at 0.05, β at 0.95, and an anticipated dropout rate of 20%, the calculation was derived according to the study by Aktar N, which investigated patients undergoing off-pump coronary artery bypass grafting10. In that study, the postoperative blood lactate levels were reported as 2.47 ± 0.93 mmol/L and 3.95 ± 1.30 mmol/L in the two groups, respectively. Substituting these parameters into the formula yielded a minimum required sample size of 20 patients per grou In our study, a total of 70 patients were enrolled and analyzed. The flow chart of the study is shown in Fig. 1 (Fig. 1: Flowchart of study). Fig. 1Flowchart of the study. Flowchart of the study. Three subjects in the EGDT group were switched to cardiopulmonary bypass due to the occurrence of ventricular fibrillation during surgery. We excluded these patients from the analysis because the use of cardiopulmonary bypass affects blood lactate levels. Therefore, they were not included in the outcome assessment. Study variables Outcome variable Hemodynamic stability was measured by hemodynamic parameters (directly) and post-operative lactate levels (indirectly). Hemodynamic parameters (directly) included mean arterial pressure (MAP), heart rate (HR), Sp02, Hct, PPV, SVV (stroke volume variation (SVV)), cardiac index (CI), and systemic vascular resistance (SVR). Postoperative blood lactate concentration measured immediately after surgery, defined as a binary variable; Hyperlactatemia: blood lactate concentration > 2.2 mmol/L; Normal lactate: blood lactate concentration ≤ 2.2 mmol/L. Independent variable Application of Early Goal-Directed Therapy (EGDT) versus control group (standard management). Baseline variables Age, sex, body mass index (BMI), body surface area (BSA), New York Heart Association (NYHA) functional classification, comorbidities, mean arterial pressure (MAP), heart rate (HR), cardiac index (CI), and systemic vascular resistance (SVR) measured at various intraoperative time points (T1: Baseline; T2: Post-induction; T3: Pre-anchoring suture; T4: Post-anchoring suture; T5: Pre-anastomosis LAD (Left Anterior Descending artery); T6: Post-anastomosis LAD; T7: Pre-anastomosis LCx (Left Circumflex artery); T8: Post-anastomosis LCx; T9: Pre-anastomosis RCA (Right Coronary Artery); T10: Post-anastomosis RCA). Research procedure Preoperative patient Preparation For elective surgeries, patients underwent a multidisciplinary preoperative consultation to ensure optimal medical stabilization before surgery. Pre-anesthesia evaluation was performed on the day before the operation to assess perioperative risk factors and develop a tailored monitoring plan. All patients meeting the inclusion criteria were invited to participate in the study and provided written informed consent. At this stage, baseline variables for each patient were recorded. Intraoperative monitoring The following monitoring modalities were employed during surgery: Continuous electrocardiography (ECG) with DII and V5 leads, with the capability for 12-lead monitoring; Invasive arterial blood pressure measurement via standard arterial catheterization or FloTrac/EV1000 system; Central venous catheterization for central venous pressure (CVP) measurement; Cardiac output (CO) monitoring, cardiac index (CI), and systemic vascular resistance (SVR) measurements; Pulse oximetry (SpO₂) and capnography (EtCO₂); Arterial blood gas analysis; Esophageal and rectal temperature monitoring; Indwelling urinary catheter for continuous urine output and color assessment. Anesthesia and controlled ventilation protocol Patients were monitored and had their hemodynamic status controlled intraoperatively using either the FloTrac/EV1000 system or conventional methods. Upon arrival in the operating room, all patients were fitted with five electrodes for continuous two-lead ECG monitoring (DII, V5), underwent non-invasive blood pressure measurement using an automated sphygmomanometer, and had pulse oximetry (SpO₂) monitoring. Oxygen was administered via face mask at 3 L/min, and a peripheral intravenous line was established. Subsequently, an internal jugular vein catheter and a radial arterial catheter were inserted under local anesthesia for invasive arterial pressure monitoring. In patients in the EGDT group—specifically those with reduced cardiac function (left ventricular ejection fraction < 50%), and/or severe left main coronary artery disease, and/or candidates for minimally invasive coronary surgery—the FloTrac/EV1000 system was additionally connected for advanced hemodynamic monitoring as directed by the attending anesthesiologist. Induction of anesthesia Sufentanil: 0.5 µg/kg; Propofol: 1–2 mg/kg, administered slowly to titrate effect; Rocuronium: 1 mg/kg; Endotracheal intubation was performed once the Train of Four (TOF) count reached 0. After confirming proper tube placement, mechanical ventilation was initiated using a Carestation 650c anesthesia machine in a closed circuit, low-flow, volume-controlled mode. Ventilator settings included tidal volume of 8–10 mL/kg, respiratory rate of 12 breaths/min, and FiO₂ of 60%. Maintenance of anesthesia Continuous intravenous infusion of: Sufentanil: 0.2–0.3 µg/kg/h; Propofol: 2–3 mg/kg/h; Rocuronium: 0.3–0.5 mg/kg/h; Anesthetic depth was maintained at a bispectral index (BIS) of 40–60. Hemodynamic and data collection time points Heart rate, blood pressure, cardiac index (CI), and systemic vascular resistance (SVR) were recorded at the following stages: T1: Baseline; T2: Post-induction; T3: Pre-anchoring suture; T4: Post-anchoring suture; T5: Pre-anastomosis LAD (Left Anterior Descending artery); T6: Post-anastomosis LAD; T7: Pre-anastomosis LCx (Left Circumflex artery); T8: Post-anastomosis LCx; T9: Pre-anastomosis RCA (Right Coronary Artery); T10: Post-anastomosis RCA. All patients in both the EGDT group and the control group were monitored using standard invasive methods, including a radial arterial line for continuous blood pressure measurement and an internal jugular central venous catheter for central venous pressure (CVP) monitoring. CVP values guided fluid therapy, while vasoactive medication adjustments were based on mean arterial pressure (MAP). The response protocol used for both groups is shown in Fig. 2. Fig. 2Response protocol for both groups. Response protocol for both groups. Anesthetic depth was managed using bispectral index (BIS) monitoring, maintained between 40 and 60. No additional advanced hemodynamic monitoring devices, such as FloTrac, were used in this group; therefore, management was not guided by extended hemodynamic parameters related to EGDT. At the conclusion of surgery, patients were transferred to the surgical intensive care unit for postoperative monitoring and management. Immediate postoperative blood sampling, including arterial lactate measurement, was performed. Our study is a case-control, cross-sectional descriptive design, focusing solely on the assessment immediately post-surgery without longitudinal follow-up for postoperative clinical endpoints such as ICU stay duration or organ dysfunction. The primary objective of monitoring lactate levels and hemodynamic parameters was to provide timely and actionable information for the Surgical ICU team to guide resuscitation efforts effectively. Table 1 Hemodynamic goal of the EGDT group and the control group. Table 1Hemodynamic goal of the EGDT group and the control group.EGDT groupControl groupMAP> 70 mmHg> 70 mmHgSp02> 95%> 95%Hct> 30%> 30%PPV< 10%PPV < 10%SVV< 13%CI≥ 2,2 L/min/m²SVR900–1200 dynes.sec.cm−5 Table 1Hemodynamic goal of the EGDT group and the control group.EGDT groupControl groupMAP> 70 mmHg> 70 mmHgSp02> 95%> 95%Hct> 30%> 30%PPV< 10%PPV < 10%SVV< 13%CI≥ 2,2 L/min/m²SVR900–1200 dynes.sec.cm−5 Hemodynamic goal of the EGDT group and the control group. Details of hemodynamic management during the coronary anastomosis phase are shown in Supplementary 1. Data analysis Data were managed using EpiData Manager. Statistical analyses were performed with STATA version 14.2. A p-value of < 0.05 was considered indicative of statistical significance. Categorical variables were compared between groups using the Chi-square test or Fisher’s exact test, as appropriate. Continuous variables with normal distribution were compared between two groups using the Student’s t-test. The association between independent variables and the outcome variable was assessed using the odds ratio (OR) with corresponding 95% confidence intervals (95% CI). Ethical considerations The study was approved by the Institutional Review Board of Military Hospital 175 (560/GCN-HĐĐĐ dated 18/06/2022). This study adhered to the principles of the Declaration of Helsinki for Biomedical Research. All participants received a clear explanation of the anesthesia and perioperative critical care procedures associated with off-pump coronary artery bypass surgery. Written informed consent to participate in the study was obtained before enrollment. Patient information was kept confidential and used solely for research purposes. Results The study included 70 patients (EGDT group: 36, control group: 34). Baseline characteristics were similar between groups (Table 2), including age (61.1 ± 8.9 vs. 64.1 ± 9.5 years, p = 0.173), sex (77.8% vs. 79.4% male, p = 0.868), BMI (23.6 ± 2.6 vs. 23.5 ± 2.4 kg/m², p = 0.902), and comorbidities (hypertension, diabetes, dyslipidemia; all p > 0.77). Heart failure was more common in the EGDT group (80.6% vs. 61.8%, p = 0.082), though not statistically significant. Hemoglobin levels trended lower in EGDT patients (12.7 ± 1.6 vs. 13.2 ± 1.4 g/dL, p = 0.139), with higher anemia prevalence (38.9% vs. 23.5%, p = 0.167). NYHA class distribution did not differ significantly (p = 0.645). Table 2Baseline characteristics.CharacteristicsTotal population (n = 70)EGDTp-valueYes(n = 36)No(n = 34) Age 62.5 ± 9.361.1 ± 8.964.1 ± 9.50.173GenderMale55 (78.6)28 (77.8)27 (79.4)0.868Female15 (21.4)8 (22.2)7 (20.6)BMI (kg/m²)23.6 ± 2.523.6 ± 2.623.5 ± 2.40.902BSA1.67 ± 0.21.65 ± 0.11.68 ± 0.20.383Co-morbidityHypertension54 (77.1)28 (77.8)26 (76.5)0.896Diabetes32 (45.7)16 (44.4)14 (47.1)0.826Heart Failure50 (71.4)29 (80.6)21 (61.8)0.082Chronic Kidney Disease4 (5.7)4 (11.1)0 (0)0.115Dyslipdemia28 (40)15 (41.7)13 (38.2)0.770Hemoglobin (g/dL)12.9 ± 1.512.7 ± 1.613.2 ± 1.40.139Anemia22 (31.4)14 (38.9)8 (23.5)0.167NYHAI21 (30)13 (36.1)8 (23.5)0.645II47 (67.1)22 (61.1)25 (73.5)III2 (2.9)1 (2.8)1 (3) Table 2Baseline characteristics.CharacteristicsTotal population (n = 70)EGDTp-valueYes(n = 36)No(n = 34) Age 62.5 ± 9.361.1 ± 8.964.1 ± 9.50.173GenderMale55 (78.6)28 (77.8)27 (79.4)0.868Female15 (21.4)8 (22.2)7 (20.6)BMI (kg/m²)23.6 ± 2.523.6 ± 2.623.5 ± 2.40.902BSA1.67 ± 0.21.65 ± 0.11.68 ± 0.20.383Co-morbidityHypertension54 (77.1)28 (77.8)26 (76.5)0.896Diabetes32 (45.7)16 (44.4)14 (47.1)0.826Heart Failure50 (71.4)29 (80.6)21 (61.8)0.082Chronic Kidney Disease4 (5.7)4 (11.1)0 (0)0.115Dyslipdemia28 (40)15 (41.7)13 (38.2)0.770Hemoglobin (g/dL)12.9 ± 1.512.7 ± 1.613.2 ± 1.40.139Anemia22 (31.4)14 (38.9)8 (23.5)0.167NYHAI21 (30)13 (36.1)8 (23.5)0.645II47 (67.1)22 (61.1)25 (73.5)III2 (2.9)1 (2.8)1 (3) Baseline characteristics. Table 3 shows the coronary artery and surgical characteristics. Left main coronary artery (LMCA) disease was present in 47.1% of patients, with a trend toward higher prevalence in the EGDT group (58.3% vs. 35.3%, p = 0.054). Most stenoses were moderate (50–70%, 51.5%) or severe (70–80%, 33.3%), with no significant differences between groups (p = 0.931). Three-vessel disease was predominant (81.4% overall), with similar rates in both groups (86.1% EGDT group vs. 76.5% control group, p = 0.3). Open surgery was performed in 90% of cases, with no group differences (p = 0.533). The majority received 2–3 vessel anastomoses (51.4% 3-vessel), and surgical/anesthesia times were comparable (p > 0.62). Blood loss was numerically lower in the EGDT group (444.4 ± 134.1 vs. 486.2 ± 110.2 mL, p = 0.161), with a trend toward more transfusions (33.3% vs. 14.7%, p = 0.069). Table 3Coronary artery and surgical characteristics.CharacteristicsTotal population (n = 70)EGDTp-valueYes (n = 36)No (n = 34)Coronary artery characteristicsLMCA (left main coronary artery)33 (47.1)21 (58.3)12 (35.3)0.054Level of stenosis50% − 70%17 (51.5)10 (47.6)7 (58.3)0.93170% − 80%11 (33.3)7 (33.4)4 (33.3)80% − 90%2 (6.1)2 (9.5)0 (0)> 90%3 (9.1)2 (9.5)1 (8.4)Number of vessel disease2 Vessel disease57 (81.4)5 (13.9)8 (23.5)0.33 Vessel disease13 (18.6)31 (86.1)26 (76.5)Surgical characteristicsType of surgeryOpen63 (90)32 (88.9)31 (91.1)0.533Minimal invasive7 (10)4 (11.1)3 (8.9)Number of vessel anastomosis15 (7.1)4 (11.1)1 (2.9)0.204227 (38.6)11 (30.6)16 (47.1)336 (51.4)19 (52.8)17 (50)42 (2.9)2 (5.5)0 (0)Surgical time (min)259.8 ± 84.1254.9 ± 68.9265.2 ± 98.40.621Anesthesia time (min)289.8 ± 84.1284.8 ± 68.9294.9 ± 98.40.622Blood loss (mL)464.7 ± 123.9444.4 ± 134.1486.2 ± 110.20.161Blood transfusion17 (24.3)12 (33.3)5 (14.7)0.069 Table 3Coronary artery and surgical characteristics.CharacteristicsTotal population (n = 70)EGDTp-valueYes (n = 36)No (n = 34)Coronary artery characteristicsLMCA (left main coronary artery)33 (47.1)21 (58.3)12 (35.3)0.054Level of stenosis50% − 70%17 (51.5)10 (47.6)7 (58.3)0.93170% − 80%11 (33.3)7 (33.4)4 (33.3)80% − 90%2 (6.1)2 (9.5)0 (0)> 90%3 (9.1)2 (9.5)1 (8.4)Number of vessel disease2 Vessel disease57 (81.4)5 (13.9)8 (23.5)0.33 Vessel disease13 (18.6)31 (86.1)26 (76.5)Surgical characteristicsType of surgeryOpen63 (90)32 (88.9)31 (91.1)0.533Minimal invasive7 (10)4 (11.1)3 (8.9)Number of vessel anastomosis15 (7.1)4 (11.1)1 (2.9)0.204227 (38.6)11 (30.6)16 (47.1)336 (51.4)19 (52.8)17 (50)42 (2.9)2 (5.5)0 (0)Surgical time (min)259.8 ± 84.1254.9 ± 68.9265.2 ± 98.40.621Anesthesia time (min)289.8 ± 84.1284.8 ± 68.9294.9 ± 98.40.622Blood loss (mL)464.7 ± 123.9444.4 ± 134.1486.2 ± 110.20.161Blood transfusion17 (24.3)12 (33.3)5 (14.7)0.069 Coronary artery and surgical characteristics. Effectiveness of EGDT Figure 3 shows mean arterial pressure changes during surgery. Both groups experienced a MAP nadir at T4 - post-anchoring suture (Control: 59.56 vs. EGDT: 62.42 mmHg). The EGDT group maintained significantly higher MAP (+ 2.86 mmHg, p = 0.044) during this vulnerable period. 48% of controls vs. 32% of EGDT patients fell below the 65 mmHg threshold (p = 0.038). The EGDT group showed faster MAP recovery post-T4 (83.83 vs. 83.41 mmHg at T5). More stable trajectory from T6-T10 with more minor fluctuations (SD: 1.2 vs. 1.8 in controls). Fig. 3Mean arterial pressure heart rate changes during surgery. Mean arterial pressure heart rate changes during surgery. Longitudinal heart rate (HR) measurements demonstrated distinct temporal patterns between groups (Fig. 4). Both groups showed similar baseline HR (Control group: 67.41 bpm vs. EGDT group: 67.81 bpm at T1), with parallel fluctuations during intermediate time points before diverging at later stages. In general, heart rate showed a slight decrease after anesthesia induction but remained within a stable range (variation < 5%) throughout the surgical procedure. Fig. 4Heart rate changes during surgery. Heart rate changes during surgery. The Cardiac Index (CI, L/min/m²) was measured at 10 time points (T1–T10) in the EGDT Group (Fig. 5). CI peaked at T1 (3.09 L/min/m²) and reached its lowest value at T4 (2.26 L/min/m²), suggesting a transient decline and mild hypoperfusion (CI normal ranges: 2.5–4.0 L/min/m²). After T4, CI gradually recovered, nearing baseline levels by T9–T10 (3.00 and 2.88 L/min/m², respectively). Fig. 5Cardiac index (CI) changes during surgery in the EGDT grou. Cardiac index (CI) changes during surgery in the EGDT grou. Longitudinal changes in systemic vascular resistance (SVR) were analyzed across 10 time points (T1–T10) (Fig. 6). SRV was lowest at T2 - Post-induction (1122.25 dynes·sec·cm⁻⁵), rising progressively to peak at T9 - Pre-anastomosis RCA. T9 value = 1374.67 approaches upper limit (SVR normal range: 900–1400 dynes·sec·cm⁻⁵). Fig. 6Systemic vascular resistance (SVR) changes during surgery in the EGDT grou. Systemic vascular resistance (SVR) changes during surgery in the EGDT grou. Table 4 shows the association between the implementation of EGDT and serum lactate concentration immediately after surgery. EGDT implementation was associated with a 70% reduction in postoperative hyperlactatemia risk (OR 0.29; 95% CI 0.08–0.97; p = 0.023). Reduced hyperlactatemia in the EGDT group suggests improved tissue perfusion, aligning with prior evidence that EGDT optimizes hemodynamics. Table 4Association between implementation of the EGDT and serum lactate concentration immediately after surgery.Serum lactateEGDTp-valueOdd ratio95% CIYesn = 36Non = 34Elevated6 (16.7)14 (41.2)0.0230.290.08–0.97Normal30 (83.3)20 (58.8) Table 4Association between implementation of the EGDT and serum lactate concentration immediately after surgery.Serum lactateEGDTp-valueOdd ratio95% CIYesn = 36Non = 34Elevated6 (16.7)14 (41.2)0.0230.290.08–0.97Normal30 (83.3)20 (58.8) Association between implementation of the EGDT and serum lactate concentration immediately after surgery. Discussion In our study, hemodynamic changes were recorded at various time points during off-pump coronary artery bypass surgery. During the induction phase, all measured parameters decreased: heart rate dropped by 4.2%, mean arterial pressure decreased by 10.1%, cardiac index fell by 10.2%, and systemic vascular resistance declined by 8.1%. The pharmacological effects of the anesthetics explain these changes, which include opioids and propofol. Opioids produce central nervous system analgesia and sympathetic inhibition, while propofol, an intravenous anesthetic, induces sedation by acting on the central nervous system. Another pharmacodynamic effect of propofol is vasodilation, which contributes to reductions in heart rate and systemic vascular resistance. Additionally, patients are typically in a state of relative hypovolemia at induction due to preoperative fasting and the combined effects of anesthesia drugs, leading to decreases in blood pressure and cardiac index immediately after induction. Therefore, we recognize that placing an arterial catheter equipped with the FloTrac/EV1000 monitoring system before anesthesia induction provides significant benefits in the EGDT. This advanced monitoring allows timely management adjustments—such as goal-directed fluid resuscitation and titration of anesthetic and vasoactive drugs—in response to changes in heart rate, blood pressure, cardiac index, stroke volume, stroke volume variation, and systemic vascular resistance during induction. This approach facilitates optimal hemodynamic stability during the critical induction phase, ultimately supporting better perioperative patient outcomes. During the phases of anastomosis of the left anterior descending artery graft, obtuse marginal artery graft, and right coronary artery graft, the cardiac index and mean arterial pressure decreased by less than 5%. This finding contrasts with the study by Srikrishna S, who reported a significant reduction in cardiac output during the coronary artery bypass grafting phases11. The discrepancy may be attributed to differences in hemodynamic management: Srikrishna S controlled hemodynamics based on central venous pressure and mean arterial pressure (MAP) above 60 mmHg, whereas our study employed the EGDT targeting parameters such as stroke volume variation, stroke volume, cardiac index, and systemic vascular resistance. Furthermore, our study found that the most substantial hemodynamic changes occurred during the pericardial stay suture placement to stabilize the heart, with a 22.1% decrease in cardiac index and a 25.7% decrease in mean arterial pressure. However, this phase lasted only about 3–5 s and was repeated twice, while each coronary graft anastomosis lasted 10–15 min. Notably, Srikrishna S’s study did not report on hemodynamic changes during this specific phase11. These differences underscore the potential advantages of using EGDT with advanced hemodynamic monitoring, as it may provide better stability during longer phases of coronary grafting, while allowing prompt management during brief but marked hemodynamic shifts such as heart stabilization maneuvers. During off-pump coronary artery bypass surgery (OPCAB), manipulation of the beating heart can cause significant hemodynamic changes such as decreases in systolic blood pressure (SBP) and cardiac index (CI), along with increases in mean pulmonary artery pressure7. These changes can critically impair myocardial oxygen delivery, leading to increased postoperative requirements for inotropic agents and vasopressors, prolonged mechanical ventilation, and extended stays in the intensive care unit. Early recognition and timely treatment of low cardiac output states are essential to improving patient outcomes after surgery4. Most anesthesiologists aim to maintain a mean arterial pressure between 70 and 100 mmHg intraoperatively to avoid low cardiac output8. However, MAP alone is not a reliable indicator of tissue perfusion because it is influenced by the interplay of cardiac output and systemic vascular resistance. Cardiac output itself depends on three key factors: preload (venous return), myocardial contractility, and afterload. Therefore, a normal MAP may still be present when cardiac output is low but SVR is elevated, which can mask inadequate tissue perfusion. Treating hypotension or low MAP during surgery without assessing these three components can result in inappropriate fluid management, excessive use of vasopressors, and increased postoperative complications1. The EGDT addresses this by continuously monitoring and managing preload, contractility, and afterload. This approach optimizes both blood pressure and cardiac output, tailoring interventions to each variable for the best possible postoperative outcomes. Continuous hemodynamic monitoring technologies such as the FloTrac/EV1000 system enable dynamic assessment of these parameters during OPCAB, allowing precise adjustments in fluid therapy, inotropes, and vasopressors. The application of EGDT using the FloTrac system for hemodynamic control during off-pump coronary artery bypass surgery significantly reduces the risk of postoperative hyperlactatemia by 70% (p = 0.023). This indicates that EGDT is effective in stabilizing hemodynamics and improving metabolic outcomes immediately after surgery. Supporting this, a study by Aktar N and colleagues found that elevated blood lactate levels measured 6 h after ICU admission are an independent risk factor for several adverse postoperative outcomes in OPCAB patients. These include prolonged mechanical ventilation, extended ICU stay, pulmonary complications, and renal dysfunction. Their reported incidence of elevated lactate immediately post-surgery was 69.3%, higher than our study’s 28.6%10. This discrepancy may stem from their higher lactate cutoff value (> 3 mmol/L) compared to our study’s threshold of 2.2 mmol/L, and the use of EGDT in our cohort for intraoperative hemodynamic management. Together, these findings highlight that controlling hemodynamics early and precisely during OPCAB with EGDT protocols such as FloTrac-based monitoring can substantially lower the incidence of hyperlactatemia, which is closely linked to adverse postoperative outcomes and complications. Thus, EGDT plays a critical role in improving both metabolic stability and clinical recovery in patients undergoing off-pump coronary artery bypass surgery. Elevated blood lactate levels after surgery are closely linked to anaerobic metabolism caused by inadequate cardiac output to perfuse the body’s organs. In the context of off-pump coronary artery bypass surgery, increased lactate also reflects myocardial ischemia resulting from surgical manipulation of the beating heart and positional changes during the procedure12. These hemodynamic alterations can reduce tissue oxygen delivery, inducing metabolic stress. Recent studies have demonstrated that high postoperative lactate levels correlate with increased morbidity and mortality in patients undergoing coronary artery bypass grafting, valve surgery, or combined procedures12,13. Elevated lactate serves as an early biochemical marker predicting complications such as prolonged mechanical ventilation, extended ICU stay, pulmonary complications, and renal dysfunction. Timely monitoring and correction of hyperlactatemia contribute to improved patient outcomes by facilitating early detection of inadequate tissue perfusion and guiding hemodynamic interventions. Consequently, postoperative lactate measurement can provide clinicians with vital early insights into the risk of adverse events following OPCAB, even in the absence of cardiopulmonary bypass. This underscores the importance of continuous, minimally invasive hemodynamic monitoring during surgery to optimize cardiac output and oxygen delivery. Furthermore, the 2024 European guidelines from EACTS/EACTAIC/EBCP for adult coronary artery bypass surgery recommend the use of minimally invasive hemodynamic monitoring modalities during OPCAB procedures. Such equipment enables real-time assessment and prompt management of hemodynamic fluctuations, helping to reduce the incidence of hyperlactatemia and associated complications14. Some studies have provided strong evidence supporting the effectiveness of EGDT in improving postoperative outcomes for patients undergoing off-pump coronary artery bypass surgery by using advanced hemodynamic targets like stroke volume variation (SVV) and cardiac index (CI) with FloTrac/EV1000 monitoring15. Kapoor et al. evaluated EGDT with FloTrac/EV1000 in OPCAB and concluded that it significantly decreased the duration of ICU stay from 4.20 ± 0.82 days to 2.53 ± 0.56 days and hospital stay from 7.42 ± 1.48 days to 5.61 ± 1.11 days (both p < 0.001)4. EGDT guided by FloTrac/EV1000 with SVV and CI goals during OPCAB reduces ICU and hospital length of stay significantly—a key point to consider for extending the outcome measures in our ongoing research. Limitations of the study Our study, which so far has focused on assessing the efficacy of EGDT in stabilizing hemodynamics through immediate postoperative blood lactate levels, has not yet examined the impact of EGDT on ICU and hospital length of stay. This represents a limitation of our research. Incorporating evaluation of ICU and hospital stay in future studies would align our work with these pivotal findings and provide a more comprehensive understanding of EGDT’s benefits in OPCAB surgical care. The small sample size and single-center design were also the limitations of our study. Recommendation As a result of our study, we recommended the new response protocol for clinical applications (Fig. 7). Fig. 7Recommendation of a new response protocol. Recommendation of a new response protocol. Conclusion Application of early goal-directed therapy in off-pump coronary artery bypass surgery showed hemodynamic stability, better control, and a statistical significance reduction in the risk of postoperative hyperlactatemia by 70%. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1